Best Practices in Protecting and Exploiting Intellectual Property
Thursday, July 17 2014
8:00 am – 10:00 am
Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA.
Intellectual Property is the lifeblood of the biopharmaceutical industry. The shifting legal landscape and budgetary pressures make it ever more challenging to effectively protect and exploit IP assets.
Our panel of experts will discuss their views on these and other topics:
- Impact of the patent reform on patent filing strategies
- Subject matter eligibility under Myriad and Prometheus: US v. Rest of the World
- How to properly project IP expenses and maximize ROI short and long-term
- Balancing disclosure, ownership, enablement and obviousness in charting out an IP strategy
- Major legal differences between biological and chemical entities
- Tools and resources available to for patent analyses and IP management
- Steven A. Kriston, JD, Regional Consultant, Innovation and Asset Management, IP Solutions, Thomson Reuters
- Robert Silverman, JD, PhD, Sr. Vice President and General Counsel, Concert Pharmaceuticals
- Jennifer Zarutskie Sieczkiewicz, JD, PhD, Director of IP Strategy and Operations, Biogen Idec
- Konstantin Linnik, JD, PhD, Partner, Intellectual Property Department, Nutter McClennen & Fish LLP
This Forum is presented by the Legal & Regulatory and Drug Discovery Forum Working Groups.
Steven A. Kriston, JD, Regional Consultant, Innovation and Asset Management, IP Solutions, Thomson Reuters
Steve Kriston has been with the Intellectual Property group at Thomson Reuters since 2008, in both management and direct client facing rolls. As Regional Consultant for Innovation & Asset Management, he currently helps organizations of all types to enhance their IP workflow capabilities in the areas of prior art search, patent analytics/technology landscaping, and optimization of IP process. Previously, he worked for many years in the legal division of Thomson Reuters, helping law firms and corporations with legal research and law practice solutions. Steve holds a JD from Seton Hall University School of Law.
Konstantin Linnik, JD, PhD, Partner, Intellectual Property Department, Nutter McClennen & Fish LLP
Konstantin Linnik is a partner in Nutter’s Intellectual Property Department and is a co-chair of the Legal & Regulatory Working Group at MassBio.
At Nutter, he works with biotech and pharma companies on various matters involving intellectual property, including IP strategy creation and execution, building and leveraging patent portfolios, competitive analysis, product design and development, licensing and negotiations, due diligence, IP audits, patent enforcement and litigation. Before joining Nutter in 2011, Konstantin was Senior Corporate Counsel at Pfizer, where he was lead patent counsel for Pfizer research units located in Cambridge, Massachusetts; Düsseldorf, Germany; and Ottawa, Canada. Prior to Pfizer, he had extensive experience representing other leading pharma and biotech companies as their external counsel.
Konstantin is currently chairs the Biotechnology Committee of the Boston Patent Law Association and is an adjunct professor at Suffolk University Law School, where teaches a course on drafting IP licenses. He earned his JD, cum laude, from Suffolk University Law School and PhD in Biophysics/Cell Biology from Boston University.
Robert Silverman, JD, PhD, Sr. Vice President and General Counsel, Concert Pharmaceuticals
Robert Silverman has been Senior Vice President and General Counsel at Concert Pharmaceuticals, Inc. in Lexington, MA since December 2010 and was the company’s Vice President and General Counsel from January 2007 to December 2010. Prior to joining Concert, he served in various legal related roles at Millennium Pharmaceuticals, Inc., Vertex Pharmaceuticals and FMC Corporation, a chemical manufacturing company where he started his career as a research chemist. Dr. Silverman received his J.D. from Rutgers-Camden Law School. He was a postdoctoral research associate at Stanford University and received a Ph.D. in organic chemistry from the University of New Mexico and a B.A. from Lehigh University. He is the author of “Patent Filings Strategies for Pharmaceutical Products: A Simple Cost-Benefit Analysis Based on Filing Costs and Pharmaceutical Sales”, AIPLA QJ, 33(2), 153 (2005) and a co-author or co-inventor on over twenty scientific publications and patents.
Jennifer Zarutskie Sieczkiewicz, JD, PhD, Director of IP Strategy and Operations, Biogen Idec
At Biogen Idec, Jen Zarutskie Sieczkiewicz works directly with various stakeholders throughout the company to align IP strategy with the company’s R&D, corporate and commercial strategies. Prior to assuming this role, she was responsible for all aspects of IP management of several immunology and neurology programs, including TYSABRI®. Before joining Biogen Idec, she was Director of IP at Dyax Corp. from 2007 to 2010, and prior to moving to in-house was an associate at Foley Hoag LLP, and Goodwin Procter LLP, both in Boston, MA. She received her J.D. from Boston University Law School, her Ph.D., in Biological Chemistry from the Massachusetts Institute of Technology, and her A.B. in Chemistry from Bryn Mawr College.